These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24753160)

  • 1. Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications.
    Graf AC; Bauer P; Glimm E; Koenig F
    Biom J; 2014 Jul; 56(4):614-30. PubMed ID: 24753160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision of maximum likelihood estimation in adaptive designs.
    Graf AC; Gutjahr G; Brannath W
    Stat Med; 2016 Mar; 35(6):922-41. PubMed ID: 26459506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum type I error rate inflation from sample size reassessment when investigators are blind to treatment labels.
    Żebrowska M; Posch M; Magirr D
    Stat Med; 2016 May; 35(12):1972-84. PubMed ID: 26694878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look.
    Graf AC; Bauer P
    Stat Med; 2011 Jun; 30(14):1637-47. PubMed ID: 21495058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
    Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
    BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive designs with arbitrary dependence structure.
    Schmidt R; Faldum A; Witt O; Gerss J
    Biom J; 2014 Jan; 56(1):86-106. PubMed ID: 24395207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-stage designs with small sample sizes.
    Kieser M; Rauch G; Pilz M
    J Biopharm Stat; 2023 Jan; 33(1):53-59. PubMed ID: 35612521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive Dunnett tests for treatment selection.
    Koenig F; Brannath W; Bretz F; Posch M
    Stat Med; 2008 May; 27(10):1612-25. PubMed ID: 17876763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim analysis and sample size reassessment.
    Posch M; Bauer P
    Biometrics; 2000 Dec; 56(4):1170-6. PubMed ID: 11129475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues in designing flexible trials.
    Posch M; Bauer P; Brannath W
    Stat Med; 2003 Mar; 22(6):953-69. PubMed ID: 12627412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I error in sample size re-estimations based on observed treatment difference.
    Shun Z; Yuan W; Brady WE; Hsu H
    Stat Med; 2001 Feb; 20(4):497-513. PubMed ID: 11223896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions.
    Broberg P
    BMC Med Res Methodol; 2013 Jul; 13():94. PubMed ID: 23870495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive designs in critical care trials: a simulation study.
    Li W; Cornelius V; Finfer S; Venkatesh B; Billot L
    BMC Med Res Methodol; 2023 Oct; 23(1):236. PubMed ID: 37853343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive dose-finding: Proof of concept with type I error control.
    Miller F
    Biom J; 2010 Oct; 52(5):577-89. PubMed ID: 20976691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.